SAFETY EVALUATION OF FLAXSEED LIGNAN SUPPLEMENTATION IN OLDER ADULTS RESIDING IN LONG-TERM CARE HOMES
N. Viveky, L. Thorpe, J. Alcorn, T. Hadjistavropoulos, S.J Whiting
Jour Nursing Home Res 2015;1:84-88
The anti-inflammatory and anti-oxidant properties of flaxseed lignans could benefit age-related chronic conditions. We aimed to examine the safety of supplementation of the major flaxseed lignan, secoisolariciresinol diglucoside (SDG) in frail older adults residing in long-term care (LTC) homes. Twenty-six older adults (60-80 years of age) met the inclusion criteria and were enrolled in a double blind randomized control trial of SDG supplementation at 300 mg/day for six months. Adverse events were recorded every week along with other blood and functionality tests. Participants in the treatment group demonstrated no evidence of hypoglycemia and hypotension or other adverse events. We conclude that SDG supplementation (300 mg/day) in a frail, complex patient population causes no significant adverse outcomes.
N. Viveky ; L. Thorpe ; J. Alcorn ; T. Hadjistavropoulos ; S.J Whiting (2015): Safety evaluation of flaxseed lignan supplementation in older adults residing in long-term care homes. The Journal of Nursing Home Research Science (JNHRS). http://dx.doi.org/10.14283/jnhrs.2015.17